期刊文献+

^(131)I-17-丙烯胺基-17-脱甲基格尔德霉素毒副作用的初步观察

The Primary Observation of Toxicity and Side-effects of ^(131)I-17-allylamino-17-demethoxygeldanamycin
下载PDF
导出
摘要 目的观察131I-17-丙烯胺基-17-脱甲基格尔德霉素(131I-17-AAG)治疗VX2肝癌移植瘤模型的骨髓及肝脏毒副作用。方法16只新西兰白兔,制成VX2荷肝癌模型后,按完全随机原则分为2组,1组(治疗组)8只,10mCi131I-17-AAG耳缘静脉注射;2组(对照组)8只,为未经治疗的荷瘤兔,1、2组荷瘤兔均分别于第1、2周耳缘静脉采血,进行血常规(白细胞、红细胞、血红蛋白、血小板)及酶学(谷草转氨酶、谷丙转氨酶、碱性磷酸酶、谷氨酰转酞酶)检查。结果2周时白细胞、红细胞和血红蛋白无显著差异(P>0.05),血小板、ALT、AST均有显著差异(P<0.05),碱性磷酸酶、谷氨酰转移酶无显著差异(P>0.05)。结论131I-17-丙烯胺基17脱甲基格尔德霉素(131I-17-AAG)对骨髓造血干细胞及肝功能各项指标有不同程度的影响,且随时间逐步得到恢复。 Objective To investigate the bone marrow side-effect and liver toxicity of the treatment on vx2 transplanted liver cancer model rabbits with 17-allylamino-17-demethoxygeldanamycin. Methods 16 New-Zealand white rabbits were made into VX2 transplanted liver cancer models and devided into two groups randomly. 8 rabbits in the first group (treatment group) were treated with 10 mCi ^131I-17-allylarnino-17-demethoxygeldanamycin by ear vein injection, and the second group(contrast group) was untreated. 1 week and 2 weeks after injection two groups were examined of white blood cells (WBC), red blood cells (RBC), blood platelet (PLT), hemoglobin (Hb), glutamate-pyruvate transaminase(ALT), glutamic-oxal (o) acetictransaminase (AST) alkaline phosphatase(ALP) 7-glutamyltransferase(GGT). Collected data were analyzed with SPSS14. 0. Results The variance of white blood cells(WBC), red blood cells(RBC), hemoglobin(Hb), alkaline phosphatase (ALP), γ- glutamyltransferase (GGT) were nonsignificant ( P 〉 0.05 ) in 2 weeks. However, the significance of variance was seen in blood platelet(PET), glutamate-pyruvate transaminase(ALT), glutamic-oxal (o) acetic transaminase (AST) at the same time ( P 〈 0.05). Conclusion The side-effects of 131I-17-allylamino-17-demethoxygeldanamycin differed in various blood items and improved with time.
出处 《实用临床医药杂志》 CAS 2007年第5期59-61,共3页 Journal of Clinical Medicine in Practice
基金 国家自然科学基金资项目(30470500) 江苏省科技厅社会发展指令性计划(BS2004020)
关键词 ^131I—17-丙烯胺基-17-脱甲基格尔德霉素 热休克蛋白90 毒副作用 ^131I-17-allylamino-17-demethoxygeldanamycin heat shock protein 90 sideeffects
  • 相关文献

参考文献11

  • 1陈奕,丁健.热休克蛋白90——癌症治疗的新靶点[J].癌症,2004,23(8):968-974. 被引量:17
  • 2姜新宇,陈道桢,刘璐.17-丙烯胺基-17-去甲氧基格尔德霉素研究进展[J].国际肿瘤学杂志,2006,33(9):646-650. 被引量:4
  • 3Powers M V, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors[J]. Endocr Relat Cancer, 2006, 13: Suppl 1: S125.
  • 4马昕,林菊生,杨志芳,黎培员,宋东坡.格尔德霉素对肝癌细胞Akt磷酸化及细胞周期的影响[J].世界华人消化杂志,2004,12(8):1793-1795. 被引量:3
  • 5Vriesendorp H M, Vriesendorp F J. A review of the intravenous administration of radiolabeled immunoglobulin G to cancer patients. High or low protein dose[J]. Cancer Biother Radiopharm, 2003, 18(1): 35.
  • 6Turrel J M, McEntee M C, Burke B P, et al. Sodium iodide I 131 treatment of dogs with nouresectable thyroid tumors: 39 cases (1990-2003) [J]. J Am Vet Med Assoc, 2006, 229 (4) : 542.
  • 7Supko J G, Hickman R L, Grever M R, et al. Preelinical pharmacologic evaluation of geldanarnycin as an antiturnor agent[J]. Cancer Chemother Pharmacol, 1995, 36(4) : 305.
  • 8Adams J, Elliott P J. New agents in cancer clinical trials[J]. Oncogene, 2000, 19: 6687.
  • 9Noker P E, Thompson R B, Smith A C, et al. Toxicity and pharmacokinetics of 17 - allylaminogeldanamycin ( 17 - AAG, NSC-330507)in dogs[J]. Proc Am Assoc Cancer Res, 1999, 40 : 804.
  • 10Page J, Heath J, Fulton R, et al. Comparison of geldanarnycin ( NSC- 122750 ) and 17 - allyaminogeldanamycin (NSC-330507) toxicity in rats[J]. Proc Am Assoc Cancer Res, 1997, 38: 2067.

二级参考文献91

  • 1Lai SL,Brauch H,Knutsen T,et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines [J]. Anticancer Res,1995,15:225- 232.
  • 2Kamal A,Thao L,Sensintaffar J,et al. A high-affinity conformation of Hsp90 confers tumour selectivity on hsp90 inhibitors [J]. Nature,2003,425:407- 410.
  • 3Morimoto RI. Regulation of the heat shock transcriptional response cross talk between a family of heat shock factors, molecular chaperones, and negative regulators [J]. Genes Dev,1998,12:3788- 3796.
  • 4Jolly C,Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death [J]. J Natl Cancer Inst,2000,92:1564- 1572.
  • 5Smith DE,Whitesell L,Katsanis E. Molecular chaperones: Biology and prospects for pharmacological intervention [J]. Pharmacol Rev,1998,50:493- 514.
  • 6Smith DF. Chaperones in signal transduction. In: Molecular chaperones in the cell [M]. P Lund(Ed.) Oxford University Press, Oxford and NY, 2001:165- 178.
  • 7Martin KJ,Kritzman BM,Price LM,et al. Linking gene expression patterns to therapeutic groups in breast cancer [J]. Cancer Res,2000,60:2232- 2238.
  • 8Conroy SE,Latchman DS. Do heat shock proteins have a role in breast cancer?[J]. Br J Cancer,1996,74:717- 721.
  • 9Kawanishi K,Shiozaki H,Doki Y, et al. Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus [J]. Cancer,1999,85:1649- 1657.
  • 10Jameel A,Skilton RA,Campbell TA,et al. Clinical and biological significance of HSP 89a in human breast cancer [J]. Int J Cancer,1992,50:409- 415.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部